This article focuses on two key innovations in dermatology: post-exposure prophylaxis for sexually transmitted infections (STIs) and new therapeutic options for inflammatory skin diseases. New European and American guidelines for doxycycline post-exposure prophylaxis (Doxy PEP) aim to prevent STIs in men who have sex with men (MSM) and individuals on HIV pre-exposure prophylaxis (PrEP). Doxy PEP is effective against syphilis and chlamydia, but its efficacy is limited by growing gonorrhea resistance. At the same time, significant progress has been made in the treatment of certain inflammatory skin diseases. Topical Janus kinase (JAK) inhibitors provide new treatment options for inflammatory skin diseases such as vitiligo and atopic dermatitis by blocking the JAK-STAT pathway. These molecules show a favorable safety profile in topical use, reducing systemic side effects.